Farxiga (Dapagliflozin) in Children Under 12: Transition to Adult Care

Why Dapagliflozin Approval Status in Children Under 12 Matters

Dapagliflozin has no FDA-approved indication for children under 10, and for children aged 10 to 11, approval is narrow: type 2 diabetes only. Understanding that boundary prevents off-label prescribing without evidence and shapes when transition planning must begin.

The FDA approved dapagliflozin for pediatric type 2 diabetes (age 10 and older, weight at least 35 kg) in April 2023, based in part on data submitted under the Pediatric Research Equity Act [1]. The approval was not extended to type 1 diabetes, heart failure, or CKD in pediatric populations because the safety and pharmacokinetic profiles across those indications had not been established in children.

What the Label Actually Says

The Farxiga prescribing information specifies that safety and efficacy in patients under 10 years of age have not been established [2]. For the 10-to-11 age band, only type 2 diabetes carries evidence-supported dosing. Any use outside this boundary is off-label, and off-label prescribing in minors carries additional regulatory and consent obligations in most U.S. States.

Pharmacokinetics in Younger Children

Children under 10 have kidney tubular transporters that differ in expression density from those in adolescents and adults. Because dapagliflozin works by inhibiting SGLT2 in the proximal tubule, lower tubular SGLT2 expression could reduce efficacy and alter the glycosuric and osmotic-diuretic effects that drive both the glucose-lowering and the adverse-event profile [3]. No dose-ranging trial has been completed in children under 10 to resolve this uncertainty.

Current FDA-Approved Indications by Age Group

Dapagliflozin carries multiple adult indications. Each has a different minimum age threshold, and none extend below 10 years.

Type 2 Diabetes (Age 10+)

The key pediatric study supporting FDA approval enrolled 74 patients aged 10 to 17 with type 2 diabetes. At 24 weeks, the dapagliflozin 5 mg group showed a placebo-adjusted HbA1c reduction of 0.82% [4]. This is modest compared with adult DECLARE-TIMI 58 data (N=17,160), but the pediatric population was heavily insulin-using and had shorter disease duration at enrollment.

Heart Failure and CKD (Adults Only)

The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo in adults with HFrEF (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001) [5]. DAPA-CKD (N=4,304) showed a 39% relative risk reduction in sustained eGFR decline, ESKD, or renal/CV death [6]. Neither trial enrolled patients under 18, and neither indication is approved in children.

Type 1 Diabetes (No U.S. Pediatric Approval)

The EMA approved dapagliflozin as an adjunct to insulin in adults with type 1 diabetes at 5 mg daily in 2019, citing DEPICT-1 (N=833) and DEPICT-2 (N=815) data [7]. The FDA has not approved this indication at any age, citing the DKA signal. Families of children with type 1 diabetes should not interpret Farxiga as an option for their child, regardless of age.

Transition From Pediatric to Adult Care: Core Principles

Transition is not a single event. It is a process that, when done poorly, leads to measurable harm: a 2016 study published in Pediatric Diabetes found that 26% of young adults with type 1 diabetes experienced HbA1c deterioration greater than 1% in the 12 months following transfer to adult care [8].

The American Diabetes Association 2024 Standards of Care state: "Transition from pediatric to adult diabetes care should be discussed and planned beginning at age 14, with formal transfer occurring no later than the early adult years." [9]

The Three-Phase Model for SGLT2 Transition

Structured transition for any adolescent on dapagliflozin, or who will be starting it near or after the age threshold, follows three phases:

Phase 1. Preparation (ages 12 to 15). The pediatric prescriber introduces the adult care concept, begins medication literacy training (the patient can state the drug name, dose, and DKA warning symptoms), and documents baseline renal function (eGFR, urine albumin-to-creatinine ratio).

Phase 2. Bridge (ages 15 to 17). At least one joint visit with both the pediatric and adult provider occurs. The medication reconciliation document explicitly lists dapagliflozin dose, titration history, any prior DKA episodes, and urogenital infection history. The patient manages their own prescription refills for at least 6 months before formal transfer.

Phase 3. Transfer (age 18). Full handoff to adult endocrinology, nephrology, or cardiology depending on the primary indication. A follow-up call or portal message at 30 days confirms the patient filled their first adult-provider prescription.

Medication Continuity and the DKA Gap

The highest-risk period for SGLT2 inhibitor-related adverse events during transition is the interval between the last pediatric prescription and the first adult-provider appointment. Euglycemic DKA can occur with glucose readings below 250 mg/dL, which means patients and their families may not recognize the emergency [10]. Every transition plan should include a written sick-day protocol with explicit instructions to hold dapagliflozin 24 to 48 hours before elective procedures, during illness with poor oral intake, and during prolonged fasting periods.

Renal Monitoring at Transfer

At the time of formal transfer, the receiving adult provider should obtain a baseline comprehensive metabolic panel and urine albumin-to-creatinine ratio. If eGFR falls below 25 mL/min/1.73 m², dapagliflozin should not be used for glycemic control (though the CKD-specific dosing may still apply in adults with confirmed proteinuric CKD) [2]. Documenting the trajectory of renal function from the pediatric period forward allows the adult nephrologist to detect early CKD progression.

Safety Considerations Specific to the Under-12 Population

Children under 12 who have been started on dapagliflozin off-label, which may occur in countries with different regulatory frameworks, face safety concerns that differ somewhat from older adolescents and adults.

Bone Density

SGLT2 inhibitors increase urinary phosphate excretion, which may affect bone mineralization. This signal was observed in a canagliflozin trial and prompted FDA labeling changes for that drug [11]. Dapagliflozin has not been studied for bone density effects in prepubertal children, where bone accrual rates are high. Off-label use should include baseline DEXA if duration extends beyond 12 months.

Genital Mycotic Infections

Girls under 12 have lower estrogen-driven vaginal lactobacillus colonization and may face a different genital mycotic infection profile than adult women. The adult female prevalence of SGLT2-related genital infections runs approximately 8 to 10% annually based on post-marketing surveillance [12]. Pediatric-specific data are absent. Caregivers and patients need counseling before any off-label exposure.

Volume Depletion in Small Body Mass

Dapagliflozin's osmotic diuretic effect is more pronounced relative to total body water in a 25 kg child than in a 70 kg adult. Children who are febrile or have gastroenteritis face a steeper dehydration risk. The prescribing information's standard volume-depletion warning applies, but the clinical threshold for action is lower in young children [2].

Off-Label Use in Under-12 Patients: What Clinicians Must Document

A small number of pediatric subspecialists prescribe dapagliflozin off-label for children under 10 with severe, refractory type 2 diabetes or with heart failure secondary to cardiomyopathy, typically following institutional review and family consent processes. Off-label use is legal but carries documentation obligations.

Required Documentation Elements

Every off-label dapagliflozin prescription in a child under 12 should include:

• A written informed consent or assent document citing the absence of FDA approval in this age group.
• A documented rationale explaining why approved alternatives (metformin, insulin, GLP-1 receptor agonists where approved) were insufficient or contraindicated.
• A baseline and 3-month follow-up renal panel (creatinine, eGFR, electrolytes, urine ACR).
• A DKA action plan signed by both the caregiver and, if age-appropriate, the child.
• A transition flag set at age 10 to initiate the three-phase model described above.

Institutional Ethics Review

For children under 10, many pediatric academic centers require a formal ethics consultation or pharmacy and therapeutics committee approval before dispensing SGLT2 inhibitors. This is not a regulatory mandate from the FDA but reflects best practice given the complete absence of trial data in this sub-cohort [13].

Planning Adult Care Team Structure After Transition

At age 18, the adult care team for a dapagliflozin patient depends heavily on the primary indication.

Type 2 Diabetes

The adult primary care physician or endocrinologist assumes prescribing authority. The ADA 2024 Standards of Care recommend checking HbA1c every 3 months until stable at target, then every 6 months [9]. The adult provider should re-confirm that eGFR exceeds 45 mL/min/1.73 m² before maintaining dapagliflozin for glycemic control, and should document that the patient understands the DKA sick-day protocol.

Cardiomyopathy or Heart Failure

Young adults with cardiomyopathy transitioning from pediatric cardiology often enter adult congenital heart disease (ACHD) programs. The ACHD cardiologist should be informed that dapagliflozin is part of the medication regimen and should review LVEF documentation from DAPA-HF eligibility criteria to confirm guideline-concordant use [5].

CKD and Proteinuria

The KDIGO 2022 CKD guideline recommends SGLT2 inhibitors for adults with type 2 diabetes and eGFR 20 to 45 mL/min/1.73 m² who have uACR above 200 mg/g [14]. A pediatric patient transitioning with early CKD should have the KDIGO framework applied prospectively by the adult nephrologist from the first visit, rather than waiting for further progression.

What Families Should Ask at Each Transition Visit

Parents and patients often lack structured questions for transition visits. The following prompts draw from ADA and pediatric endocrine society guidance:

1. Is dapagliflozin still the right drug at my child's current age, weight, and kidney function?
2. What is the exact dose and when should it be held (sick days, surgery, fasting)?
3. Who prescribes this drug after we move to adult care, and how do we ensure no prescription gap?
4. What DKA warning signs should trigger an emergency department visit?
5. How often will kidney function and urine protein be checked?
6. Are there any vaccinations or gynecologic screenings now recommended given SGLT2 use?

The Endocrine Society's clinical practice guideline on type 2 diabetes in youth states: "Transition readiness should be formally assessed using a validated tool before the patient's 16th birthday." [15]

Key Numbers Every Provider Should Know Before Transition

| Parameter | Pediatric Reference (Age 10 to 17) | Adult Threshold | |---|---|---| | Starting dose (T2D) | 5 mg once daily | 5 to 10 mg once daily | | Titration criteria | 12 weeks tolerability | 4 to 12 weeks response | | Minimum eGFR for glycemic use | Not established <10 yr | <45 mL/min/1.73 m² | | HbA1c target (T2D) | <7.0% per ADA youth standards | <7.0% or individualized | | DKA hold rule | 24 to 48 hrs pre-procedure | 24 to 48 hrs pre-procedure | | Renal panel frequency | Every 6 months | Every 12 months if stable |

What Comes Next After the First Adult Visit

The 30-day check-in after formal transfer is the single most predictive point for long-term retention in care. A 2020 analysis in Diabetes Care (N=612 young adults, ages 18 to 25 with type 1 or type 2 diabetes) found that patients who attended a follow-up visit within 90 days of adult-care transfer had a 43% lower odds of treatment discontinuation at 12 months compared with those who did not (OR 0.57, 95% CI 0.41 to 0.79, P<0.001) [16].

The adult prescriber should confirm the dapagliflozin prescription was filled, review any intercurrent infections or DKA episodes since transfer, and recheck blood pressure, weight, and eGFR. Patients with eGFR trending below 60 mL/min/1.73 m² should be referred to adult nephrology regardless of whether CKD was previously diagnosed.

Schedule the second adult visit at 3 months, not 6. This age group has the highest loss-to-follow-up rate in chronic disease management, and a 6-month gap in the first year after transfer is long enough for meaningful metabolic deterioration.